logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5145.produseast1
Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial | Journal Article / Research | MSF Science Portal
Journal Article
|Research

Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial

Rangaka MX, Wilkinson RJ, Boulle AM, Glynn JR, Fielding K, van Cutsem G, Wilkinson KA, Goliath R, Mathee S, Goemaere E, Maartens G
Download

Similar Content
Loading...
Loading...
Loading...
Abstract
Antiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the effect of isoniazid preventive therapy on the risk of tuberculosis in people infected with HIV-1 concurrently receiving antiretroviral therapy.

Countries

South Africa

Subject Area

tuberculosisHIV/AIDS

Languages

English
DOI
10.1016/S0140-6736(14)60162-8
Published Date
14 May 2014
PubMed ID
24835842
Journal
Lancet
Volume | Issue | Pages
Volume null Issue 9944
Issue Date
2014-08-01
Dimensions Badge